{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:21:01Z","timestamp":1790194861020,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vascn.2024.107524","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T20:02:18Z","timestamp":1717790538000},"page":"107524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions."],"prefix":"10.1016","volume":"128","author":[{"given":"Derek J.","family":"Leishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Brimecombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Crumb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hebeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Kilfoil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Melliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2024.107524_bb0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vascn.2018.01.488","article-title":"Use of hERG binding in lead optimization provides greater predictivity for QTc prolongation in vivo compared to manual patch hERG assay","volume":"93","author":"Abernathy","year":"2018","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107524_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3219","article-title":"The efficacy, effectiveness, and efficiency of integrated QTc assessment: Rationalizing approaches to new drug modalities","author":"Abernathy","year":"2024","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"8","key":"10.1016\/j.vascn.2024.107524_bb0015","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.bjp.0706678","article-title":"Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin","volume":"147","author":"Alexandrou","year":"2006","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.vascn.2024.107524_bb0020","first-page":"511","article-title":"The human ethera\u2019-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: Limited dependence on S6 aromatic residues","volume":"65","author":"Alexandrou","year":"2014","journal-title":"Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.vascn.2024.107524_bb0025","series-title":"The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals : ICH S7B","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.vascn.2024.107524_bb0030","unstructured":"Anonymous (2022). ICH E14\/S7B implementation working group - clinical and nonclinical evaluation of QT\/QTc interval prolongation and Proarrhythmic potential. Questions and Answers."},{"key":"10.1016\/j.vascn.2024.107524_bb0035","series-title":"ICH E14\/S7B Q&As Training Material Examples Supplemental File","author":"Anonymous","year":"2022"},{"key":"10.1016\/j.vascn.2024.107524_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.vascn.2017.02.021","article-title":"Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia assay (CiPA): An industry survey on current practice","volume":"86","author":"Authier","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107524_bb0045","doi-asserted-by":"crossref","unstructured":"Balduzzi, S., R\u00fccker, G., & Schwarzer, G. (2019). How to perform a meta-analysis with R: A practical tutorial. In evidence-based mental health (issue 22, pp. 153\u2013160).","DOI":"10.1136\/ebmental-2019-300117"},{"key":"10.1016\/j.vascn.2024.107524_bb0050","article-title":"Detection of QTc effects in small studies-implications for replacing the thorough QT study","author":"Ferber","year":"2014","journal-title":"Annals of Noninvasive Electrocardiology"},{"issue":"2","key":"10.1016\/j.vascn.2024.107524_bb0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"issue":"7","key":"10.1016\/j.vascn.2024.107524_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.vascn.2024.107524_bb0065","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clpt.2005.02.004","article-title":"A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data","volume":"77","author":"Jonker","year":"2005","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2024.107524_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174584","article-title":"Characterization of a high throughput human stem cell cardiomyocyte assay to predict drug-induced changes in clinical electrocardiogram parameters","volume":"912","author":"Kilfoil","year":"2021","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2024.107524_bb0075","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: Superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.vascn.2024.107524_bb0080","first-page":"614","article-title":"Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels","volume":"295","author":"Kuryshev","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2024.107524_bb0085","article-title":"Revisiting the hERG safety margin after 20 years of routine hERG screening","volume":"106900","author":"Leishman","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107524_bb0090","first-page":"1502","article-title":"Assessment of an in SilicoMechanistic model for Proarrhythmia risk prediction under the CiPA initiative","volume":"154","author":"Li","year":"2018","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"5","key":"10.1016\/j.vascn.2024.107524_bb0095","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bjp.0705335","article-title":"Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652","volume":"139","author":"Milnes","year":"2003","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2024.107524_bb0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vascn.2010.02.007","article-title":"Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37\u00b0C: Cisapride versus dofetilide","volume":"61","author":"Milnes","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2024.107524_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2016.04.007","article-title":"Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes","author":"Pfeiffer","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2024.107524_bb0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2024.107524_bb0120","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2023"},{"issue":"1","key":"10.1016\/j.vascn.2024.107524_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.vascn.2024.107524_bb0130","article-title":"A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm","volume":"114961","author":"Ridder","year":"2020","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2024.107524_bb0135","article-title":"Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&as","volume":"107270","author":"Rossman","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2024.107524_bb0140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00031305.1980.10483031","article-title":"Population marginal means in the linear model: An alternative to least squares means","volume":"34","author":"Searle","year":"1980","journal-title":"The American Statistician"},{"key":"10.1016\/j.vascn.2024.107524_bb0145","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","author":"Strauss","year":"2020","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2024.107524_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicting drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2024.107524_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2023.107265","article-title":"Improving the in vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute","volume":"121","author":"Vargas","year":"2023","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2024.107524_bb0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1476-5381.2009.00395.x","article-title":"Integrated risk assessment and predictive value to humans of non-clinical repolarization assays","volume":"159","author":"Wallis","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2024.107524_bb0165","first-page":"116","article-title":"Towards a drug concentration effect relationship for QT prolongation and torsades de pointes","volume":"5","author":"Webster","year":"2002","journal-title":"Current Opinion in Drug Discovery & Development"},{"issue":"1","key":"10.1016\/j.vascn.2024.107524_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/data5010010","article-title":"An open-access dataset of thorough QT studies results","volume":"5","author":"Wi\u015bniowska","year":"2020","journal-title":"Data"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:09:37Z","timestamp":1737756577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871924000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"alternative-id":["S1056871924000340"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107524","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions.","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107524"}}